Rein Therapeutics Inc Cash Flow-to-Debt Ratio
Rein Therapeutics Inc cash flow-to-debt ratio. Rein Therapeutics Inc (RNTX) has a Cash Flow-to-Debt Ratio of -0.15x as of June 2026, meaning its operating cash flow of $-8.64 Million could theoretically repay 0% of its total liabilities ($55.77 Million) in one year. See Rein Therapeutics Inc free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Rein Therapeutics Inc (2015–2025)
Cash flow-to-debt ratio of Rein Therapeutics Inc from 2015 to 2025. Historical debt coverage capacity for Rein Therapeutics Inc across 11 annual periods. Also explore RNTX year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Rein Therapeutics Inc Cash Flow-to-Debt Ratio by Year (2015–2025)
Rein Therapeutics Inc cash flow-to-debt ratio by year from 2015 to 2025. Year-by-year debt coverage analysis for Rein Therapeutics Inc. For the full cash flow conversion analysis, see RNTX operating cash flow.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -2.67x | $-19.36 Million | $7.24 Million | ▼ -78.1% |
| 2024 | -1.50x | $-22.29 Million | $14.85 Million | ▼ -651.3% |
| 2023 | -0.20x | $-19.81 Million | $99.12 Million | ▲ +97.3% |
| 2022 | -7.35x | $-24.86 Million | $3.38 Million | ▼ -41.6% |
| 2021 | -5.19x | $-23.75 Million | $4.58 Million | ▼ -5.9% |
| 2020 | -4.90x | $-20.48 Million | $4.18 Million | ▼ -92.9% |
| 2019 | -2.54x | $-26.47 Million | $10.43 Million | ▲ +2.6% |
| 2018 | -2.61x | $-27.93 Million | $10.71 Million | ▲ +37.9% |
| 2017 | -4.20x | $-20.53 Million | $4.89 Million | ▼ -3641.6% |
| 2016 | -0.11x | $-15.01 Million | $133.83 Million | ▲ +3.9% |
| 2015 | -0.12x | $-11.71 Million | $100.26 Million | — |